Bubbly: an edible pearl for intestinal microbiome modulation
Presented by: UGent2_Belgium
Bénédicte Améry1 , Bram Jacobs1 , Milan Van Nuffel1 , Louis Coussement2 , Lien De Wannemaeker2 , Jose Manuel Salvador Lopez2 , Michiel Stock2 , Marjan De Mey3 & Wim Van Criekinge4.
1 iGEM student member, 2 Instructor, 3 Primary PI (Center for Synthetic Biology (CSB), Faculty of Bioscience Engineering, Ghent University, Belgium), 4 Secondary PI (BIOBIX, Faculty of Bioscience Engineering, Ghent University, Belgium).
Project Abstract
The WHO estimates that more than 300 million people worldwide suffer from depression (WHO, 2020).
Research has shown that gut microbiome alternations play a key role in a person’s stress
reactivity and influences anxiety-like and depression-like behaviors. In brief, if we can manage
to alter the gut microbiome’s functionality, the bidirectional communication might shift and
lead to less anxiety and depression-like behaviors. We believe that Bubbly can revert
depression and to bring relief to people suffering from depression. Our pearl, a novel food
supplement, is composed of three major components: naringenin, a flavonoid that works
anti-inflammatory, kojibiose, a prebiotic sugar with beneficial effects on the gut microbiome
and vitamin-B12. Now, we are producing naringenin in the lab and working on the
formulation of the pearl. Our pearl can be sold as an independent product and could also be
added to already existing foods as probiotics.
Team:UGent2 Belgium/Poster
Poster: UGent2_Belgium
Bubbly: an edible pearl for intestinal microbiome modulation
Project Goals
We want to produce an edible bubble which:
1. Tastes and feels good
2. Survives the stomach acid and releases in the small intestines
3. Helps reducing the microbial imbalance due to stress
This way hope to be able to play a supporting role in restoring the microbial balance in the gut and hence restoring the gut-brain axis.
Inspiration
We started out with kombucha in a quest to make a food product to battle vitamin deficiencies, a worldwide problem. It turned out however that this is still subject to a lot of debate, combined with the difficulty of designing a new stable culture in a product which is centuries old we decided to move on.
One of the main problems we kept running into was the need for an efficient way of transporting the needed nutrients to the place of uptake without them being destroyed prematurely. So, with feedback from our principal investigators and literature research, we decided to make a U-turn and tackle this specific carrier problem. We did so by making an edible carrier-bubble which can safely pass the stomach with its valuable content still intact. This bubble will then arrive in the small intestine where it will release its active components.
One of the main problems we kept running into was the need for an efficient way of transporting the needed nutrients to the place of uptake without them being destroyed prematurely. So, with feedback from our principal investigators and literature research, we decided to make a U-turn and tackle this specific carrier problem. We did so by making an edible carrier-bubble which can safely pass the stomach with its valuable content still intact. This bubble will then arrive in the small intestine where it will release its active components.
A visual representation of us changing our initial plan :p
Problem
The WHO estimates that more than 300 million people worldwide suffer from depression. It is also the world's leading cause of functional disorder. Also, the recent COVID-19 pandemic led to a tremendous increase in the prevalence of depression symptoms in people throughout the world. Since it would take years to reduce the long-term effects of this world-wide crisis, the prevalence of depression will still increase in the coming years(Ettman et al., 2020; Mencaccia & Salvib, 2021).
Patients nowadays get drugs like antidepressants prescribed to combat these feelings, whereas only one-third of all patients get the desired release of depression and anxiety. Research has shown that the intestinal microbiome alterations play a crucial role in a person's stress reactivity and influences depression-like behaviors. It is called the (microbiome-)gut-brain axis. The relative abundance of Bacteroidetes species (e.g. Prevotella) is increased, and the relative abundance of Firmicutes (e.g. Faecalibacterium and Ruminococcus) is decreased in patients with depression (Liang et al., 2018). This leads to a disbalance in the homeostasis of gut bacteria, also known as dysbiosis. Furthermore, dysbiosis occurs together with a state of inflammation in the gut. Hence leading to increased physical discomfort.
Patients nowadays get drugs like antidepressants prescribed to combat these feelings, whereas only one-third of all patients get the desired release of depression and anxiety. Research has shown that the intestinal microbiome alterations play a crucial role in a person's stress reactivity and influences depression-like behaviors. It is called the (microbiome-)gut-brain axis. The relative abundance of Bacteroidetes species (e.g. Prevotella) is increased, and the relative abundance of Firmicutes (e.g. Faecalibacterium and Ruminococcus) is decreased in patients with depression (Liang et al., 2018). This leads to a disbalance in the homeostasis of gut bacteria, also known as dysbiosis. Furthermore, dysbiosis occurs together with a state of inflammation in the gut. Hence leading to increased physical discomfort.
Idea
Following the study on depression, we concluded that there are multiple factors involved in causing depression but also in maintaining the state of depression. The first two factors are dysbiosis and inflammation. They are positively related to each other, and it is not yet known what causes what (Vitetta et al., 2014). Is it the inflammation that causes dysbiosis? Or dysbiosis that causes inflammation? So we decided to tackle both factors at the same time.
A third factor is genetics; some people have a predisposition towards depression. This does not mean that we cannot aid in reducing the symptoms associated with the psychopathology of depression. As a last factor, there is the environment. Traumatizing events like losing a job, death of a close relative or a friend can make a person more susceptible to depression (Steenbergen et al., 2015; Axt-Gadermann & Rautenberg, 2017). We want to work on reducing the first two factors actively. As for the other factors, research indicates the bilateral relationship between the severity of the pathology and the gut microbiome, hence decreasing the severity of the symptoms is our goal here.
We want to select components that have anti-inflammatory effects and promote the growth of good gut bacteria. Furthermore, we know from previous research on vitamin deficiencies that people with a higher amount of vitamin B12 have a better mental health (Berk et al., 2013; Dash et al., 2015). Also, inflammation and dysbiosis reduce the uptake of vitamin B12. Hence we hypothesized that it might be a good idea to add vitamin B12.
But how do we get all these compounds towards their site of action? For this, we hypothesized creating a certain carrier system, that contains these three components and shuttles them to their site of action. The design needs to resist the gastric environment of the stomach and has to be released over time of the ingredients it contains.
From literature we know that there are four genes involved in the tyrosine ammonia-lyase (TAL)-pathway to produce naringenin (Ganesan et al., 2017).
We will need to introduce these four genes in E. coli TOP10 if we want to produce naringenin. However, production of naringenin in E. coli is not that successful. Hence, we decided to look for another host that is more suitable to produce naringenin. A host that preferably grows on green and cheap materials. By working with multiple hosts, we will need to work with a plasmid that is suitable for multiple hosts, a selection marker to see if the organism took up the plasmid and a constitutive promoter that works in multiple hosts.
A third factor is genetics; some people have a predisposition towards depression. This does not mean that we cannot aid in reducing the symptoms associated with the psychopathology of depression. As a last factor, there is the environment. Traumatizing events like losing a job, death of a close relative or a friend can make a person more susceptible to depression (Steenbergen et al., 2015; Axt-Gadermann & Rautenberg, 2017). We want to work on reducing the first two factors actively. As for the other factors, research indicates the bilateral relationship between the severity of the pathology and the gut microbiome, hence decreasing the severity of the symptoms is our goal here.
We want to select components that have anti-inflammatory effects and promote the growth of good gut bacteria. Furthermore, we know from previous research on vitamin deficiencies that people with a higher amount of vitamin B12 have a better mental health (Berk et al., 2013; Dash et al., 2015). Also, inflammation and dysbiosis reduce the uptake of vitamin B12. Hence we hypothesized that it might be a good idea to add vitamin B12.
But how do we get all these compounds towards their site of action? For this, we hypothesized creating a certain carrier system, that contains these three components and shuttles them to their site of action. The design needs to resist the gastric environment of the stomach and has to be released over time of the ingredients it contains.
From literature we know that there are four genes involved in the tyrosine ammonia-lyase (TAL)-pathway to produce naringenin (Ganesan et al., 2017).
We will need to introduce these four genes in E. coli TOP10 if we want to produce naringenin. However, production of naringenin in E. coli is not that successful. Hence, we decided to look for another host that is more suitable to produce naringenin. A host that preferably grows on green and cheap materials. By working with multiple hosts, we will need to work with a plasmid that is suitable for multiple hosts, a selection marker to see if the organism took up the plasmid and a constitutive promoter that works in multiple hosts.
Methodology
Our methodology consists of two parts:
We developed a carrier system, a bubble, that transports microbiome modulating components towards specific sites in the gut. To study release of the components, we used a modeling system.
Next, we wanted to produce one of those microbiome-modulating components. The component of interest is naringenin.
We developed a carrier system, a bubble, that transports microbiome modulating components towards specific sites in the gut. To study release of the components, we used a modeling system.
Next, we wanted to produce one of those microbiome-modulating components. The component of interest is naringenin.
Naringenin Production
Current production methods of naringenin are non-sustainable and non-green. New ways of naringenin production using microorganisms are rising but struggle to get high quantities of naringenin. So, we attempted to produce naringenin using Cupriavidus necator PHB-4. This strain of C. necator has enhanced acetyl–CoA flux. A limited flux of acetyl-CoA is the bottleneck to produce high titers of naringenin. Furthermore C. necator is able to use glycerol as a carbon source, which is a waste stream from bioethanol production. Hence, C. necator is a green host that is well-suited to produce naringenin (Trantas et al., 2009, 2015).
The genes we want to use to produce naringenin were selected after a brief literature review and after reviewing which genes are present in-house. These are fjTAL, tyrosine ammonia-lyase from Flavobacterium johnsoniae (Jendresen et al., 2015; Haslinger & Prather, 2019); pc4CL, 4-coumaryl-CoA ligase from Petroselinum crispum ; phCHS_MUT, chalcone synthase from Petunia hybrida msCHI, chalcone isomerase from Medicago sativa (Wu et al., 2014; Zang et al., 2019).
Multiple hosts are involved in the process of cloning, testing, and producing naringenin, so we need a broad-host-range plasmid and promotor. Hence, we used pBBR1-MCS2 plasmid, which is a broad-host-range-plasmid. For the expression of the genes, we used the constitutive P22 promoter (De Mey et al., 2007).
We first tested the efficiency of the promoter in different hosts by evaluating the expression levels of mKate2, a fluorescent reporter protein, over a period of 24 hours of E.coli and 48 hours for C. necator. One result was obtained for the promoter efficiency in E.coli K12 MG1655 and indicated that there is expression of mKate2 by the P22 promoter.
The genes we want to use to produce naringenin were selected after a brief literature review and after reviewing which genes are present in-house. These are fjTAL, tyrosine ammonia-lyase from Flavobacterium johnsoniae (Jendresen et al., 2015; Haslinger & Prather, 2019); pc4CL, 4-coumaryl-CoA ligase from Petroselinum crispum ; phCHS_MUT, chalcone synthase from Petunia hybrida msCHI, chalcone isomerase from Medicago sativa (Wu et al., 2014; Zang et al., 2019).
Multiple hosts are involved in the process of cloning, testing, and producing naringenin, so we need a broad-host-range plasmid and promotor. Hence, we used pBBR1-MCS2 plasmid, which is a broad-host-range-plasmid. For the expression of the genes, we used the constitutive P22 promoter (De Mey et al., 2007).
We first tested the efficiency of the promoter in different hosts by evaluating the expression levels of mKate2, a fluorescent reporter protein, over a period of 24 hours of E.coli and 48 hours for C. necator. One result was obtained for the promoter efficiency in E.coli K12 MG1655 and indicated that there is expression of mKate2 by the P22 promoter.
After successful testing of the promoter, we wanted to compare production efficiency of E. coli K12 MG1655 and C. necator PHB-4. First, we wanted to test this in Erlenmeyer flasks and then continue to upscale to fermentation reactors. Sampling would occur over a period of 24 and respectively 48 hours. We also wanted to test production of naringenin when C. necator
uses glycerol as a carbon-source. Next to upscaling the production method, we were also working on the optimization of the downstream processing of naringenin extraction, purification, and detection.
Building the Bubble
To tackle depression, we selected three active components that affect the gut microbiome.
To produce a bubble that selectively delivers components to the gut, we contacted a company called CosmoGroup. They aided in formulating the bubble.
Naringenin, a plant flavonoid, that has anti-inflammatory effects. The reason for this is that dysbiosis is correlated with inflammation and inflammation triggers dysbiosis. Hence, naringenin has the capacity to reduce the inflammation and restore the microbiome balance (Bugianesi et al. 2002).
Kojibiose, a low-calorie sweetener with prebiotic effects, feeds only the good gut bacteria and adds a sweet flavour to our bubble (Beerens et al., 2017).
Vitamin B12 directly influences depression and is related to a higher prevalence of Faecalibacterium prausnitzii
To produce a bubble that selectively delivers components to the gut, we contacted a company called CosmoGroup. They aided in formulating the bubble.
Iterative testing of the bubble is done by using tests that are an in vitro representation of the gut and by using dissolution tests. All of these methods are standardized. Later testing is done using the SHIME, which is the closest representation of in vitro testing possible.
Additional note, for this last paragraph only the theoretical groundwork has been laid.
The Model
We created three models that replace a planned experiment. In this experiment, we wished to measure the release of naringenin ,one of our three active components, from the bubble to the environment. Due to limited access to the lab, we came up with our models.
We consider three different approaches:
We wish to remark that these models are a simplification of reality where we do not take factors as pH and intestinal motility into account. These are all improvements that will be incorporated in new models and experiments. We postpone them to a more suitable time, when access to the lab is less restricted.
Diffusion within a solid sphere: The naringenin molecules migrate to the pearl's surface and diffuse in the medium. The model is based on a system of partial differential equations.
Bubble as a solid sphere: The naringenin concentration is constant in the pearl. This model is valuable when the pearl is small and/or the diffusion is very rapid. This model is based on a ordinary differential equation.
Bubble as a dissolving sphere: The bubble dissolves; this means that diffusion is negligible since naringenin is released when the bubble dissolves. This model is based on a ordinary differential equation.
We wish to remark that these models are a simplification of reality where we do not take factors as pH and intestinal motility into account. These are all improvements that will be incorporated in new models and experiments. We postpone them to a more suitable time, when access to the lab is less restricted.
Integrated Human Practices
Our integrated human practices are dividable into three main parts: consulting experts, getting in touch with our target audience and reflecting on our project.
First, we contacted experts from the beginning to the end of our project. They guided us through every step and were constantly involved in our project. They gave us feedback regarding technical details like experts in medical fields or experts with a background in pharmaceutical chemistry and so on. Equally as important were the experts who provided us with knowledge about the social context. They helped us with questions like which people are suffering from depression, how do we get in touch with them, how should we ask our questions to remain neutral and get relevant information.
This way, we were able to get in touch with our audience by making for example a survey which gauged their interest in this product and providing us with feedback straight from our target group.
As a last part, we talked with experts about our final idea and how it would still be feasible and functional in a real-world scenario. This way we could refine our product in some domains, however some other issues are still not solved. For example how can we make sure our product will not be used as a mere symptom relief drug which does not work on the external situation which got them there in the first place. It should be considered as a food supplement, used additionally with their treatment.
First, we contacted experts from the beginning to the end of our project. They guided us through every step and were constantly involved in our project. They gave us feedback regarding technical details like experts in medical fields or experts with a background in pharmaceutical chemistry and so on. Equally as important were the experts who provided us with knowledge about the social context. They helped us with questions like which people are suffering from depression, how do we get in touch with them, how should we ask our questions to remain neutral and get relevant information.
This way, we were able to get in touch with our audience by making for example a survey which gauged their interest in this product and providing us with feedback straight from our target group.
As a last part, we talked with experts about our final idea and how it would still be feasible and functional in a real-world scenario. This way we could refine our product in some domains, however some other issues are still not solved. For example how can we make sure our product will not be used as a mere symptom relief drug which does not work on the external situation which got them there in the first place. It should be considered as a food supplement, used additionally with their treatment.
Conclusion
As all teams did, we thought this would be a year full of practical lab work, perfect to practice our theoretical knowledge. However before we set foot in the lab, even before we had our final idea on the drawing board, COVID-19 struck. Frankly at that point we thought it was over, we talked to other teams about how they were going to deliver anything more than ideas and some of them had great ideas. However, luckily for us, the labs did eventually reopen albeit with strict limitations. This is the reason that we still managed to take some of our ideas from the drawing board into the real world.
From the two species of bacteria we used, only one of them yielded results. Not surprisingly, this were the E. coli strains, rather than the Cupriavidus necator strain. However, it turned out after all the lab work by collecting all petri dishes, we possibly did found some naringenin production. Unfortunately, our tests were not able to pick this up. For E. coli K12 MG1655 however got substantial results, expressing mKate2 by the P22 promoter. Besides the wet lab, we of course also have our diffusion models that provides us some information about the naringenin release from the bubble.
All things considered, we were lucky to be able to spend some time on our practical aspect, however with mixed results. Further research is therefore much needed.
From the two species of bacteria we used, only one of them yielded results. Not surprisingly, this were the E. coli strains, rather than the Cupriavidus necator strain. However, it turned out after all the lab work by collecting all petri dishes, we possibly did found some naringenin production. Unfortunately, our tests were not able to pick this up. For E. coli K12 MG1655 however got substantial results, expressing mKate2 by the P22 promoter. Besides the wet lab, we of course also have our diffusion models that provides us some information about the naringenin release from the bubble.
All things considered, we were lucky to be able to spend some time on our practical aspect, however with mixed results. Further research is therefore much needed.
Acknowledgements
Acknowledgements
Benedicte AmeryBram Jacobs
Milan Van Nuffel
Ir. Louis Coussement
Ir. Lien De Wannemaeker
José Manuel Salvador Lopez
Dr. Ir. Michiel Stock
Prof. Dr. Ir Marjan De Mey
Prof. Dr. Ir Wim Van Crieckinge
Sponsors
References
Axt-Gadermann M & Rautenberg R (2017) Slim en gelukkig dankzij gezonde darmen Dedicon, Grave Available at: https://www.bibliotheek.nl/catalogus/titel.412601192.html/slim-en-gelukkig-dankzij-gezonde-darmen/
Beerens K, De Winter K, Van de Walle D, Grootaert C, Kamiloglu S, Miclotte L L, Van de Wiele T, Van Camp J, Dewettinck K, Koen & Desmet T. (2017) Biocatalytic Synthesis of the Rare Sugar Kojibiose: Process Scale-Up and Application Testing J. Arg and Food Chem. 65(29): 6030-6041. Available at https://pubs.acs.org/doi/abs/10.1021/acs.jafc.7b02258.
Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML & Maes M (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 11: 200 Available at: http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-200
Bugianesi R, Catasta G, Spigno P, D’Uva A & Maiani G (2002) Naringenin from cooked tomato paste is bioavailable in men. J. Nutr. 132: 3349–3352 Available at: https://pubmed.ncbi.nlm.nih.gov/12421849/
Dash S, Clarke G, Berk M & Jacka FN (2015) The gut microbiome and diet in psychiatry: Focus on depression. Curr. Opin. Psychiatry 28: 1–6 Available at: https://pubmed.ncbi.nlm.nih.gov/25415497/
De Mey M, Maertens J, Lequeux GJ, Soetaert WK & Vandamme EJ (2007) Construction and model-based analysis of a promoter library for E. coli: An indispensable tool for metabolic engineering. BMC Biotechnol. 7: 34 Available at: http://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-7-34
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020). Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Network Open, 3(9), e2019686. https://doi.org/10.1001/jamanetworkopen.2020.19686
Ganesan V, Li Z, Wang X & Zhang H (2017) Heterologous biosynthesis of natural product naringenin by co-culture engineering. Synth. Syst. Biotechnol. 2: 236–242
Liang S, Wu X, Hu X, Wang T & Jin F (2018) Recognizing depression from the microbiota–gut–brain axis. Int. J. Mol. Sci. 19: Available at: /pmc/articles/PMC6032096/?report=abstract
Mencaccia, C., & Salvib, V. (2021). Expected effects of COVID-19 outbreak on depression incidence in Italy. Journal of Affective Disorders, January, 1–2. https://doi.org/10.1016/j.jad.2020.09.043
Steenbergen L, Sellaro R, van Hemert S, Bosch JA & Colzato LS (2015) A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain. Behav. Immun. 48: 258–264 Available at: https://doi.org/10.1016/j.bbi.2015.04.003
Svihus, B., & Itani, K. (2019). Intestinal Passage and Its Relation to Digestive Processes. Journal of Applied Poultry Research, 28(3), 546–555. https://doi.org/10.3382/japr/pfy027
Trantas E, Panopoulos N & Ververidis F (2009) Metabolic engineering of the complete pathway leading to heterologous biosynthesis of various flavonoids and stilbenoids in Saccharomyces cerevisiae. Metab. Eng. 11: 355–366 Available at: https://pubmed.ncbi.nlm.nih.gov/19631278/
Trantas EA, Koffas MAG, Xu P & Ververidis F (2015) When plants produce not enough or at all: Metabolic engineering of flavonoids in microbial hosts. Front. Plant Sci. 6: 1–16 Available at: www.frontiersin.org
Vitetta L, Bambling M & Alford H (2014) The gastrointestinal tract microbiome, probiotics, and mood. Inflammopharmacology 22: 333–339
WHO (2020) Depression. Available at: https://www.who.int/news-room/fact-sheets/detail/depression